ArticleClinical pharmacology and therapeutics2018
Response to "Antiretroviral Therapy With Efavirenz in HIV-Infected Pregnant Women: Understanding the Possible Mechanisms for Drug-Drug Interaction".
Prasanna Jagannathan, Richard Kajubi, Francesca T Aweeka
Abstract readLetterComment
In one paragraphArticle in Clinical pharmacology and therapeutics, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 99% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed, 0 citations in OpenAlex.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
5 · Who and what moneyAuthors and funding
3 authors at 3 institutions in 2 countries.
Prasanna JagannathanDepartment of Medicine, Stanford University, Stanford, California, USA.
Richard KajubiInfectious Disease Research Collaboration, Kampala, Uganda.
Francesca T AweekaDepartment of Clinical Pharmacy, University of California, San Francisco, San Francisco General Hospital, San Francisco, California, USA.
Infectious Diseases Research Collaboration · UGSan Francisco General Hospital · USStanford University · US
Funding
Virology CoreP30AI027763 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI STEVEN Grant DEEKS · 1988 to 2026
$93.6MThe immunologic consequences of prenatal exposure to malariaP01HD059454 · NICHD · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI HAVLIR, DIANE V · 2008 to 2017
$22.6MOptimizing HIV-malaria treatment in a shifting treatment and resistance landscape in AfricaR01HD068174 · NICHD · YALE UNIVERSITY · PI FRANCESCA T. AWEEKA, SUNIL PARIKH · 2011 to 2026
$8.1MPharmacological insights into antimalarial exposure, clinical outcomes, and drug resistance in AfricaR01AI117001 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI AWEEKA, FRANCESCA T., ROSENTHAL, PHILIP JON · 2015 to 2024
$7.1MImmunologic Consequences of Highly Effective Antimalarial ChemopreventionK23AI100949 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI JAGANNATHAN, PRASANNA · 2012 to 2016
$657kNIAID NIH HHS K23 AI100949NIAID NIH HHS P30 AI027763NIAID NIH HHS R01 AI117001NICHD NIH HHS P01 HD059454NICHD NIH HHS R01 HD068174
6 · The paper itselfAbstract
PubMed holds no abstract for this paper.
Indexed as
HIV InfectionsMalariaAlkynesArtemisininsBenzoxazinesChemopreventionCyclopropanesDrug InteractionsFemaleHIVHumansPiperazinesPregnancyQuinolinesAlkynesArtemisininsartenimolBenzoxazinesCyclopropanesefavirenzpiperaquinePiperazinesQuinolines
Identifiers
PMID29322501
PMCPMC5847448
OpenAlexW2783298194
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390